Author: admin

“Is that all?” Very little investment needed to save US$ 100 trillion in AMR costs!

An interview with Lord Jim O’Neill, Chair, The Review on Antimicrobial Resistance, by Garance Fannie Upham, Editor, AMR Control Question: The Review on AMR has emerged as a major expertise and advocacy group globally in the movement to face antimicrobial resistance (AMR); you come from the financial sector yourself, how do you view the engagement of investors, ministers of finance development banks in AMR ? Jim O’Neill: The simple truth is that until our AMR Review commenced – and hence its purpose – outside of the specialized health world, there was very little awareness, never mind focus, on AMR....

Read More

African countries facing AMR: the input of e-Health and digital high technology

Franck Mansour Adéoti, Africa Regional Director, International Network for Planning and Improving Quality and Security in Health Systems in Africa (INPIQS/RIPAQS); Hyppolite Agboton, Secretary, Scientific Affairs, RESHAOC (Network of Hospitals of Africa, Indian Ocean and the Caribbean), Benin; Serge Coffié, Technical Adviser to the Minister, Digital Economy and Postal Services, Ivory Coast, Dr Joseph Boguifo, President, Association of Private Clinics (ACPCI) and the Private Health Sector Platform in the Ivory Coast (PSPSCI); Mireille Dosso, Director, Pasteur Institute, Ivory Coast; Stanislas Sansan Kambou, Director, Health Research and Information Systems, West African Health Organization (WAHO), Patrick Ismaila Mbengue, President, Information and...

Read More

The evolution of the global antibiotic resistance partnership

Hellen Gelband, Associate Director for Policy, Center for Disease Dynamics, Economics & Policy (CDDEP) The article provides an update on the work the Global Antibiotic Resistance Partnership established by the Center for Disease Dynamics, Economics & Policy and its increasing involvement in developing national antimicrobial resistance plans globally. The Global Antibiotic Resistance Partnership (GARP), a successful initiative of the Center for Disease Dynamics, Economics & Policy (CDDEP) to help low- and middle-income countries (LMICs) develop country-led responses to antimicrobial resistance (AMR), was profiled in AMR Control 2015. The significant uptake in global action on AMR has brought changes in emphasis...

Read More

More shots on goal: towards an innovation ecosystem sufficient for the fight against antimicrobial resistance

Adrian Thomas and Jaak Peeters, Johnson & Johnson Johnson & Johnson is the world’s most broadly based health-care company, with a longstanding commitment to and leadership in innovative technology platforms that advance human health. These include pharmaceuticals, biologicals and vaccines, as well as device and surgical innovations in orthopaedics, trauma and general surgery. As such, we understand the challenges in developing novel technologies to combat antibiotic and antiviral resistance against transmissible health security threats like tuberculosis, and the risks that resistant micro-organisms pose to patients in emergency and elective surgeries. We understand the scope of these dangers and their potential to claim millions of lives across both advanced and less developed health-care systems. We are committed to advancing the policies and technologies that will drive forward progress in this field. This year, from the World Health Assembly to the G7 meetings, world leaders have rightly emphasized the importance of an urgent, global response to the growing tide of antimicrobial resistance (AMR).  The threats AMR pose to human health are real and increasingly visible. A stream of recent reports illustrates their seriousness. In Nigeria, for example, 88% of Staphylococcus aureaus infections can no longer be treated successfully with methicillin (1). In India, of the 30 health-care workers who contracted tuberculosis at one hospital this year, 26 of them were diagnosed with multidrug-resistant TB (MDR-TB) (2). And containment of clostridium difficile...

Read More